Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activated HSC in vitro or in vivo with synthetic PPARgamma ligands suppresses the fibrogenic activity of HSC. However, it is uncertain whether PPARgamma is indeed a molecular target of this effect, because the ligands are also known to have receptor-independent actions. To test this question, the present study examined the effects of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical features of culture-activated HSC. The vector-mediated expression of PPARgamma itself is sufficient to reverse the morphology of activated HSC to the quiescent phenotype with retracted cytoplasm, prominent dendritic processes, reduced stress fibers, and accumulation of retinyl palmitate. These effects are abrogated by concomitant expression of a dominant negative mutant of PPARgamma that prevents transactivation of but not binding to the PPAR response element. PPARgamma expression also inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1; DNA synthesis; and JunD binding to the activator protein-1 (AP-1) site and AP-1 promoter activity. Inhibited JunD activity by PPARgamma is not due to reduced JunD expression or JNK activity or to a competition for p300. But it is due to a JunD-PPARgamma interaction as demonstrated by co-immunoprecipitation and glutathione S-transferase pull-down analysis. Further, the use of deletion constructs reveals that the DNA binding region of PPARgamma is the JunD interaction domain. In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [127]
Citations
Cites
1 retracted
Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade
Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., Kadowaki, T., Takeuchi, Y., Shibuya, H., Gotoh, Y., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb942 · Cited by 292
RetractedAdipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Self-citationGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Bissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118055 · Cited by 419
Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.9365 · Cited by 409
Janknecht, R., & Hunter, T. (1996) · Nature · doi:10.1038/383022a0 · Cited by 393
Saxena, N. K., Ikeda, K., Rockey, D. C., Friedman, S. L., & Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.32029 · Cited by 382
Research works printed but not linked: 8
- Kojima, 2000, Blood, 95, 1309
- Buck, 2000, Am. J. Physiol., 278, G321
- Hellerbrand, 1998, Am. J. Physiol., 275, G269
- Tsukamoto, 1996, Am. J. Physiol., 270, G581
- Xiong, 2001, Hepatology, 34, 520A
- Friedman, 1993, Am. J. Physiol., 264, G947
- Gressner, 1996, Kidney Int. Suppl., 54, S39
- Salbert, 1993, Mol. Endocrinol., 7, 1347
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“In addition, activated cells express high levels of alpha Smooth Muscle Actin (α-SMA) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) which contribute to the changes from a adipocytic phenotype to a pro-fibrogenic and inflammatory phenotype [54,55].”
BackgroundLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397
Self-citationPPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Self-citationThe Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Adipogenic Transcriptional Regulation of Hepatic Stellate Cells
She, H., Xiong, S., Hazra, S., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410078200 · Cited by 299
Self-citationRoles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Multigenerational epigenetic adaptation of the hepatic wound-healing response
Zeybel, M., Hardy, T., Wong, Y. K., Mathers, J. C., Fox, C. R., Gackowska, A., Oakley, F., Burt, A. D., Wilson, C. L., Anstee, Q. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2893 · Cited by 279
The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells
Bruschi, F. V., Claudel, T., Tardelli, M., Caligiuri, A., Stulnig, T. M., Marra, F., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.29041 · Cited by 268
Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., & Szabo, G. (2009) · Hepatology · doi:10.1002/hep.22711 · Cited by 263
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis
Cheng, J. H., She, H., Han, Y.-P., Wang, J., Xiong, S., Asahina, K., & Tsukamoto, H. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00263.2007 · Cited by 258
Self-citationThe Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
“…role for PPARb/d in hepatotoxicity is in direct contrast to a protective role of ligand activation of PPARc in hepatotoxicity where it has been shown that PPARc ligands can inhibit stellate cell activation and likely protect against liver toxicity (Hazra et al., 2004; Miyahara et al., 2000).”
BackgroundInvolvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 239
Asahina, K., Tsai, S. Y., Li, P., Ishii, M., Maxson, R. E., Sucov, H. M., & Tsukamoto, H. (2009) · Hepatology · doi:10.1002/hep.22721 · Cited by 238
Self-citationColl, M., Perea, L., Boon, R., Leite, S. B., Vallverdú, J., Mannaerts, I., Smout, A., El Taghdouini, A., Blaya, D., Rodrigo-Torres, D., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.027 · Cited by 233
Povero, D., Panera, N., Eguchi, A., Johnson, C. D., Papouchado, B. G., de Araujo Horcel, L., Pinatel, E. M., Alisi, A., Nobili, V., & Feldstein, A. E. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.07.007 · Cited by 221
Hardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311526 · Cited by 216
Zhou, X., Zang, X., Ponnusamy, M., Masucci, M. V., Tolbert, E., Gong, R., Zhao, T. C., Liu, N., Bayliss, G., Dworkin, L. D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040457 · Cited by 186
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“The MeCP2-mediated transdifferentiation of HSCs is, in part, regulated by the two distinct histone methyltransferases EZH2 and ASH1 [179].”
BackgroundFiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183
“…receptor with JunD in HSCs has already been shown (Hazra et al., 2004) since peroxisome proliferator-activated receptor- overexpression leads to formation of a JunD-peroxisome proliferator-activated receptor- complex, which prevents JunD binding to the AP-1 binding site (Hazra et al., 2004).”
BackgroundYamaguchi, Y., Cavallero, S., Patterson, M., Shen, H., Xu, J., Kumar, S. R., & Sucov, H. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417232112 · Cited by 173
Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Morelli, A., Pruzanski, M., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085597 · Cited by 177
“Despite the fact FXR and PPARγ are expressed by HSCs and ligands for these receptors decrease the expression of myo-fibroblastic markers in HSCs (Galli et al., 2000; Marra et al., 2000; Hazra et al., 2004), their expression shows opposite regulation during the process of trans-differentiation.”
BackgroundMicroRNAs in fibrosis: opportunities and challenges
O’Reilly, S. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0929-x · Cited by 165
“This is important as PPAR is critical in the shift from a quiescent to a myofibroblast in hepatic stellate cells [29].”
BackgroundMolecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies
Li, J.-T., Liao, Z.-X., Ping, J., Xu, D., & Wang, H. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2180-y · Cited by 167
Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis
Rabieian, R., Boshtam, M., Zareei, M., Kouhpayeh, S., Masoudifar, A., & Mirzaei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26146 · Cited by 161
Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
Mechanisms of alcohol‐induced hepatic fibrosis: A summary of the Ron Thurman Symposium†
Purohit, V., & Brenner, D. A. (2006) · Hepatology · doi:10.1002/hep.21107 · Cited by 161
Chen, A., & Xu, J. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00209.2004 · Cited by 158
Alcohol induced hepatic fibrosis: Role of acetaldehyde
Mello, T., Ceni, E., Surrenti, C., & Galli, A. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.10.001 · Cited by 160
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.033 · Cited by 165
Son, G., Hines, I. N., Lindquist, J., Schrum, L. W., & Rippe, R. A. (2009) · Hepatology · doi:10.1002/hep.23186 · Cited by 162
Self-citationWnt signaling in liver fibrosis: Progress, challenges and potential directions
Miao, C., Yang, Y., He, X., Huang, C. Z., Huang, Y., Zhang, L., Lv, X., Jin, Y. J., & Li, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.09.003 · Cited by 155
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 157
Gravina, G. L., Festuccia, C., Marampon, F., Popov, V. M., Pestell, R. G., ZANI, B. M., & Tombolini, V. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-305 · Cited by 160
“Another important mediator of transdifferentiation and fribrinogenesis is PPARg whose transcriptional silencing activity is required for conversion of hepatic stellate cells to myofibroblast [172].”
BackgroundWettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 132
Planagumà, A., Clària, J., Miquel, R., López‐Parra, M., Titos, E., Masferrer, J. L., Arroyo, V., & Rodé, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2753fje · Cited by 133
Yang, M. D., Chiang, Y., Higashiyama, R., Asahina, K., Mann, D. A., Mann, J., Wang, C. C. C., & Tsukamoto, H. (2011) · Hepatology · doi:10.1002/hep.24792 · Cited by 144
Self-citationThe types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies
Xu, J., Liu, X., Koyama, Y., Wang, P., Lan, T., Kim, I.-G., Kim, I. H., Ma, H.-Y., & Kisseleva, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00167 · Cited by 126
“Consistently, overexpression of PPARγ in aHSCs/myofibroblasts in vitro results in reversion of HSC activation, and reacquisition of their adipogenic characteristics (Hazra et al., 2004; Jaster et al., 2005).”
BackgroundHuman hepatic stellate cell isolation and characterization
Shang, L., Hosseini, M., Liu, X., Kisseleva, T., & Brenner, D. A. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1404-4 · Cited by 137
Liu, N., Feng, J., Lu, X., Yao, Z., Liu, Q., Lv, Y., Han, Y., Deng, J., & Zhou, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/6175091 · Cited by 147
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
Transcriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119
“PPARγ inhibition of collagen production operates through direct physical interaction between PPARγ and JunD, one of AP-1 proteins that drives collagen I transcription [122].”
BackgroundPPARs Mediate Lipid Signaling in Inflammation and Cancer
Michalik, L., & Wahli, W. (2008) · PPAR Research · doi:10.1155/2008/134059 · Cited by 117
“Activation of PPARα and PPARγ reduces proliferation and stimulates differentiation of cultured melanocytes [77, 78].”
BackgroundRecent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes
Sahini, N., & Borlak, J. T. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.02.002 · Cited by 129
Zheng, S., & Chen, A. (2004) · Biochemical Journal · doi:10.1042/bj20040928 · Cited by 123
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01285 · Cited by 110
The stellate cell system (vitamin A-storing cell system)
Senoo, H., Mezaki, Y., & Fujiwara, M. (2017) · Anatomical Science International · doi:10.1007/s12565-017-0395-9 · Cited by 123
Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis
Yang, L., Chan, C.-C., Kwon, O.-S., Liu, S., McGhee, J., Stimpson, S. A., Chen, L. Z., Harrington, W. W., Symonds, W. T., & Rockey, D. C. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00124.2006 · Cited by 109
Chen, A., & Zheng, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707542 · Cited by 111
“Forced expression of exogenous PPARg cDNA is sufficient to reverse the morphology of activated HSC to the quiescent pheno- type (Hazra et al., 2004).”
BackgroundStellate Cells in Tissue Repair, Inflammation, and Cancer
Sherman, M. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062855 · Cited by 103
Lemoine, M., Barbu, V., Girard, P. M., Kim, M. J., Bastard, J., Wendum, D., Paye, F., Housset, C., Capeau, J., & Serfaty, L. (2006) · AIDS · doi:10.1097/01.aids.0000206503.01536.11 · Cited by 118
Panebianco, C., Oben, J. A., Vinciguerra, M., & Pazienza, V. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0438-x · Cited by 111
Yin, Y., Russell, R. G., Dettin, L. E., Bai, R., Wei, Z.-L., Kozikowski, A. P., Kopleovich, L., & Glazer, R. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3990 · Cited by 101
Epigenetic reprogramming in liver fibrosis and cancer
Wilson, C. L., Mann, D. A., & Borthwick, L. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.011 · Cited by 96
Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M. (2010) · Gut · doi:10.1136/gut.2009.186528 · Cited by 96
Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
Schon, H.-T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00033 · Cited by 97
“…to hepatic fibrosis, PPARγ plays a central role in the activation of HSCs, as PPARγ expression alone is enough to restore the quiescent phenotype in activated HSCs (Hazra et al., 2004) and both activation and proliferation of HSCs correspond to exhausted PPARγ expression (Zhang et al., 2013).”
BackgroundZhou, Y., Zheng, S., Lin, J., Zhang, Q.-J., & Chen, A. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700532 · Cited by 96
In vitro reversion of activated primary human hepatic stellate cells
El Taghdouini, A., Najimi, M., Sancho-Bru, P., Sokal, E., & van Grunsven, L. A. (2015) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-015-0031-z · Cited by 91
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
“Further studies in vitro demonstrated that activated HSCs can be phenotypically and functionally reversed to quiescent HSCs by restored expression (via an adenoviral vector) or stimulated expression (via a selective agonist) of PPAR[98, 183].”
BackgroundHepatic stellate cells and parasite-induced liver fibrosis
Anthony, B. J., Allen, J., Li, Y. S., & McManus, D. P. (2010) · Parasites & Vectors · doi:10.1186/1756-3305-3-60 · Cited by 105
“This treatment has been used on activated primary rat HSC and has been shown to cause a decrease in collagen synthesis, an increase in PPARg expression and restoration of the adipogenic phenotype of quiescent HSC [50,51].”
MethodFarglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Anti‐adipogenic regulation underlies hepatic stellate cell transdifferentiation
Tsukamoto, H., She, H., Hazra, S., Cheng, J., & Miyahara, T. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04573.x · Cited by 87
Self-citationZhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 92
“PPARc was also able to directly interact with the transcription factor JunD but did not affect its expression, disrupting JunD binding to AP-1 promoter that promotes collagen I transcription in activated HSCs [38].”
BackgroundLin, J., & Chen, A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.20 · Cited by 95
PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
Monroy-Ramírez, H. C., Galicia‐Moreno, M., Sandoval-Rodriguez, A. S., Meza-Ríos, A., Santos, A., & Armendáriz‐Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158298 · Cited by 90
“Accordingly, PPARγ restoration prompts the change in activated HSC to quiescent HSC and suppresses activity of AP1 [86].”
BackgroundNakano, Y., Kamiya, A., Sumiyoshi, H., Tsuruya, K., Kagawa, T., & Inagaki, Y. (2020) · Hepatology · doi:10.1002/hep.30965 · Cited by 86
Zeybel, M., Luli, S., Sabater, L., Hardy, T., Oakley, F., Leslie, J., Page, A., Moran Salvador, E., Sharkey, V., Tsukamoto, H., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.004 · Cited by 84
Self-citationHepatic Stellate Cell-derived Delta-like Homolog 1 (DLK1) Protein in Liver Regeneration
Zhu, N.-L., Asahina, K., Wang, J., Ueno, A., Lazaro, R., Miyaoka, Y., Miyajima, A., & Tsukamoto, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312751 · Cited by 85
“Indeed, our research demonstrates that adipogenic transcription regulation is required for HSC differentiation (3, 4), and a loss of this regulation underlies HSC transdifferentiation into myofibroblastic cells (4, 5) where canonicalWnt signaling is shown to play a major role (6) much like in inhibition of adipogenesi…”
BackgroundMethodSelf-citationLiver Fibrosis: Causes and Methods of Assessment, A Review
Karimzadeh Toosi, A. E. (2015) · Romanian Journal Of Internal Medicine · doi:10.1515/rjim-2015-0039 · Cited by 84
Zheng, S., & Chen, A. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00450.2005 · Cited by 89
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S., Goodman, Z., Patel, K., Krag, A., Christiansen, C., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00283.2016 · Cited by 82
Yu, J. Q., Zhang, S., Chu, E. S., Go, M. Y. Y., Lau, R. H. Y., Zhao, J., Wu, C., Tong, L., Zhao, J., Poon, T. C. W., et al. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.006 · Cited by 84
Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
Rockey, D. C. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.005 · Cited by 79
Emerging role and therapeutic implication of Wnt signaling pathways in liver fibrosis
Wang, J.-N., Li, L., Li, L.-Y., Yan, Q., Li, J., & Xu, T. (2018) · Gene · doi:10.1016/j.gene.2018.06.053 · Cited by 76
Self-citationRegulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 86
Wei, J., Bhattacharyya, S., & Varga, J. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833de1a7 · Cited by 74
Zheng, S., & Chen, A. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00200.2006 · Cited by 77
Choi, J. H., Jin, S. W., Choi, C. Y., Kim, H. G., Lee, G. H., Kim, Y.-A., Chung, Y., & Jeong, H. G. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04805 · Cited by 78
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
“Overexpression of PPARγ in HSC, or treatment with the endogenous PPARγ ligand 15d-PGJ2 or TZDs, resulted in decreased myofibroblastic character of HSCs, with reduced collagen production and increased MMP activity (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000; Hazra et al., 2004).”
BackgroundAdipogenic Phenotype of Hepatic Stellate Cells
Tsukamoto, H. (2005) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000189279.92602.f0 · Cited by 73
Self-citationPeroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 75
Kai, S. U. N., Wang, Q., & Huang, X. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00299.x · Cited by 71
Li, X., CHEN, Y., Wu, S., He, J., Lou, L., Ye, W., & WANG, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2846 · Cited by 73
Self-citationYu, Q., Cheng, P., Wu, J., & Guo, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16267 · Cited by 74
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Park, J., Ki, M.-R., Lee, H.-R., Hong, I., Ji, A., Ishigami, A., Park, S., Kim, J., Chung, H., Yoo, S., et al. (2009) · Hepatology · doi:10.1002/hep.23499 · Cited by 71
Lee, S. J., Yang, E. K., & Kim, S. G. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022954 · Cited by 71
“This paralleled the observation that thiazolidinediones inhibited hepatic stellate cell activation (Marra et al., 2000; Hazra et al., 2004).”
Wang, C., Liu, Q., Huang, Q., Liu, J. T., He, Y. H., Lu, J., & Bai, X. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.02.001 · Cited by 69
“PPAR s essential for HSC quiescence (Hazra et al. 2004; She et al. 2005).”
BackgroundZhang, F., Lu, Y., & Zheng, S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.11.008 · Cited by 73
CDKN2a/p16 Antagonizes Hepatic Stellate Cell Activation and Liver Fibrosis by Modulating ROS Levels
Lv, F., Li, N., Kong, M., Wu, J., Fan, Z., Miao, D., Xu, Y., Ye, Q., & Wang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00176 · Cited by 65
“…reports have portrayed the nuclear receptor PPARγ as a key regulator of HSC quiescence, either by inhibiting the pro-fibrotic JunD activity (Hazra et al., 2004), by inducing an adipogenic trans-differentiation program (She et al., 2005), or by suppressing ROS production (Hsu et al., 2013).”
BackgroundSung, C. K., She, H., Xiong, S., & Tsukamoto, H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2003 · Cited by 63
Self-citationThe Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
Yavrom, S., Chen, L., Xiong, S., Wang, J., Rippe, R. A., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510094200 · Cited by 62
Self-citationAdiponectin Regulation of Stellate Cell Activation via PPARγ-Dependent and -Independent Mechanisms
Shafiei, M. S., Shetty, S., Scherer, P. E., & Rockey, D. C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.035 · Cited by 63
Metadata
- Authors
- Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of Cambridge (GB)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 12
- Pages
- 11392-11401
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091296342
- Cited by
- 320
- References
- 38
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 17 · 2020: 15 · 2019: 11 · 2018: 13 · 2017: 17 · 2016: 16 · 2015: 19 · 2014: 11 · 2013: 13 · 2012: 10
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs (P50AA11999)
- University of Southern California (P30DK48522)
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24 AA12885, P50-AA11999, R37AA006603, R37-AA-06603, R24AA012885, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-48522, P30DK048522)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- PPARγ, hepatic stellate cells, liver fibrosis, myofibroblast transdifferentiation, JunD, AP-1 transcription factor, PPARγ ligands, retinyl palmitate, alpha-smooth muscle actin, type I collagen, TGF-β1, adenoviral gene transfer
- MeSH terms
- Retinyl Esters, Animals, Binding Sites, Cell Division, Cells, Cultured, Diterpenes, Liver, Male, Phenotype, Transcription Factors, Vitamin A, Polymerase Chain Reaction, Rats, Wistar, DNA, Complementary, Receptors, Cytoplasmic and Nuclear, Transcription Factor AP-1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.